Login to Your Account



$30M in Hand, Ipierian Steers ‘True North’

By Marie Powers
Staff Writer

Wednesday, September 4, 2013

Armed with a $30 million financing, privately held Ipierian Inc. took the bold move of launching spinout True North Therapeutics, with a portion of the funds serving as the newco’s Series A. Nancy Stagliano, who serves as CEO of both companies, said the decision to split was driven by advancements in Ipierian’s two monoclonal antibody (mAb) programs, targeting the tau protein and complement pathways.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription